Key terms
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SRPT news
Nov 21
7:10am ET
J.P. Morgan Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Nov 20
6:15am ET
Buy Rating for Sarepta Therapeutics: Significant Pipeline Potential and Strategic Growth Trajectory
Nov 19
7:26am ET
TD Cowen Remains a Buy on Sarepta Therapeutics (SRPT)
Nov 19
7:05am ET
Sarepta Therapeutics: Strong Market Position and Growth Potential Amidst Limited Competition
Nov 19
6:45am ET
Buy Rating on Sarepta Therapeutics: Confidence in Elevidys’ Market Potential and Strategic Expansion
Nov 11
7:01am ET
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)
Nov 11
6:56am ET
Sarepta recent weakness brings buying opportunity, says JPMorgan
Nov 08
7:29am ET
Strong Financial Performance and Strategic Advancements Support Sarepta Therapeutics’ Buy Rating
Nov 08
2:27am ET
Sarepta Therapeutics: Strong Elevidys Sales Drive Buy Rating Amid Portfolio Optimism and Favorable Valuation
Nov 07
12:05pm ET
Qualcomm, Moderna report quarterly beats: Morning Buzz
Nov 07
9:56am ET
JPMorgan, Five Below downgraded: Wall Street’s top analyst calls
Nov 07
8:47am ET
Sarepta price target raised to $150 from $148 at Guggenheim
Nov 07
8:37am ET
Evercore ISI Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
Nov 07
8:17am ET
Strong Q3 Performance and Future Growth Prospects Justify Buy Rating on Sarepta Therapeutics
Nov 07
6:57am ET
Sarepta price target lowered to $193 from $200 at Baird
Nov 07
6:50am ET
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Sarepta Therapeutics (SRPT) and Syndax Pharmaceuticals (SNDX)
Nov 07
6:48am ET
RBC Capital Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Nov 07
6:41am ET
Piper Sandler Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Nov 07
6:35am ET
Strong Financial Performance and Promising Growth Prospects Justify Buy Rating for Sarepta Therapeutics
Nov 07
6:17am ET
Sarepta Therapeutics: Strong Elevidys Sales Drive Upward Revision and Buy Rating
Nov 07
5:40am ET
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT) and Cytokinetics (CYTK)
Nov 07
5:40am ET
Sarepta Therapeutics’ Strong Elevidys Sales Drive Buy Rating Amid Optimistic Growth Outlook
Nov 07
5:30am ET
Sarepta price target raised to $209 from $203 at Barclays
Nov 07
5:00am ET
Sarepta upgraded to Overweight from Neutral at Cantor Fitzgerald
Nov 07
4:56am ET
Sarepta Therapeutics: Strong Growth and Strategic Focus Justify Buy Rating
Nov 06
11:19pm ET
Sarepta Therapeutics Shows Financial Growth in 2024
Nov 06
7:30pm ET
Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
Nov 06
4:18pm ET
Sarepta reports Q3 EPS 62c, consensus (13c)
Nov 06
1:50pm ET
Notable companies reporting after market close
Oct 24
11:06am ET
Strong International Sales and Strategic Growth Drive Buy Rating for Sarepta Therapeutics
Oct 24
10:48am ET
Optimistic Buy Rating for Sarepta Therapeutics Amid Strong International Demand and Collaborative Potential
Nov 07
9:19am ET
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
Nov 06
6:30pm ET
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Nov 04
1:44pm ET
Viatris to Report Q3 Earnings: What's in the Cards?
Nov 04
1:43pm ET
Gilead Science to Report Q3 Earnings: What's in the Cards?
SRPT Financials
Key terms
Ad Feedback
SRPT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SRPT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
